Drug sales forecasts to 2030 reflect solid underlying demand. But much is changing across the biopharmaceutical landscape.
Despite macroeconomic headwinds, regulatory flux, and intensifying pricing scrutiny, the global pharmaceutical market continues to deliver resilient growth. Prescription drug sales are projected to surpass $1.75 trillion by 2030, representing a compound annual growth rate of over 7%. For investors, this signals a sector with enduring fundamentals—but also one undergoing structural transformation.
The World Preview report offers a strategic lens on the forces shaping the future of biopharma. We explore high-impact therapeutic innovations, disruptive market entrants, and the transformative influence of China’s expanding role and AI-driven R&D on dealmaking and pipeline productivity.
Key Highlights:
- GLP-1s dominate: Projected to account for nearly 9% of global drug sales by 2030
- China’s biotech boom: Chinese-origin assets will make up nearly 40% of global licensing deals in 2025
- Patent cliffs ahead: Over $300 billion in sales at risk by 2030
